Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FRAmework-01: Sofetabart Mipitecan in Ovarian Cancer
NCT07213804Phase 3Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2025
- Primary completion
- Nov 2028
- Countries
- 27
01
Overview
A Phase 3 trial of sofetabart mipitecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Eli Lilly and Company. Started Oct 2025; status: recruiting.
02
Drugs
sofetabart mipitecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT07213804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07213804.